Companies Dominating the Wound Care Biologics Landscape
- Marine Polymer Technologies, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Smith & Nephew
- Molnlycke Health Care AB
- Integra LifeSciences Corporation
- Wright Medical Group N.V.
- MiMedx Group, Inc.
- Vericel Corporation
- Anika Therapeutics
- Osiris Therapeutics, Inc.
- Solsys Medical, LLC
- Lavior Pharma Inc.
Numerous important companies in the wound care biologics sector are implementing several tactical measures and are constantly collaborating, expanding, making agreements, and taking part in joint ventures to fortify their positions in the industry.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of wound care biologics is assessed at USD 2.04 billion.
The wound care biologics market size was over USD 1.95 billion in 2024 and is projected to reach USD 3.82 billion by 2037, witnessing around 5.3% CAGR during the forecast period i.e., between 2025-2037. Rising cases of chronic wounds such as ischemic ulcers and foot ulcers among diabetic patients will fuel the market growth.
North America industry is estimated to dominate majority revenue share of 45% by 2037, due to growing number of wound care procedures in the region.
The major players in the market are Smith & Nephew, Molnlycke Health Care AB, Integra LifeSciences Corporation, Wright Medical Group N.V., MiMedx Group, Inc., Vericel Corporation, Anika Therapeutics, Osiris Therapeutics, Inc., Solsys Medical, LLC, Lavior Pharma Inc., and others.
